Immunogenicity and Safety of Vaccination Against Tick Borne Encephalitis (TBE) in Patients Living With Multiple Sclerosis (MS) (MS and TBE vac)

November 17, 2026 updated by: Insel Gruppe AG, University Hospital Bern

This is a monocenter, prospective cohort study. The study investigates the response of patients living with multiple sclerosis (MS) to vaccination against tick-borne viral encephalitis (TBE).

The prevalence of TBE has increased significantly in Switzerland over the past two decades. Whereas previously only the lowland regions of northern Switzerland and the Aare Valley were considered areas where TBE vaccination was indicated, the disease is now endemic throughout Switzerland (except for Ticino). Since TBE specifically affects the nervous system, there is a clear indication for vaccination, particularly for people whose nervous system is already compromised.

MS is the most common neurological autoimmune disease among young adults in northern latitudes. It is a progressive disease characterized by a gradual deterioration of neurological functions. The course of the disease can be slowed through immunomodulatory therapies. However, these therapies also lead to a certain degree of immunosuppression, which may reduce the immune response to vaccinations. At the same time, some people with MS experience fear or scepticism towards vaccinations, as infections often lead to a worsening of symptoms or can trigger a relapse. Since vaccinations mimic an infection to some extent, this concern is sometimes transferred to vaccinations as well.

The study hypothesizes that the TBE vaccine in people living with MS on non-B-cell depleting treatment shows adequate immunogenicity.

Moreover, the study will assess the safety of TBE vaccination.

Study Overview

Status

Recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

50

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

The investigators target a sample size of 50 people living with MS with stable RRMS (no evidence of disease activity -NEDA-3 status - as defined by no clinical relapse, no EDSS worsening and no new MS-lesions on MRI) for ≥ 1 year prior to inclusion into the study and treated with non-B-cell depleting therapies for at least 6 months in monotherapy.

In order to have a homogenous and stable patient population, the investigators decided to include only patients without evidence of disease activity for at least 1 year prior to inclusion. Considering the latter the investigators classify any disease reactivation during the period of 42 days (+/- 7days) after the first dose / booster dose as related to the intervention (vaccination).

Description

Inclusion Criteria

  • Adult (≥ 18 years old)

  • Suspected neuroimmunological disorder with CNS affection

    • including suspicion of Multiple Sclerosis (MS)
    • Diagnosed Multiple Sclerosis (MS)
    • Clinically Isolated Syndrome
    • Radiologically Isolated Syndrome
  • stable RRMS - defined as no evidence of disease activity-NEDA-3 status-as defined by no clinical relapse, no EDSS worsening and no new MS-lesions on MRI for ≥ 1 year prior to inclusion

  • treated with non-B-cell depleting therapies for at least 6 months in monotherapy

  • TBE vaccine:

    • never been vaccinated against TBE or
    • clinical indication for booster vaccination (person living with MS and has had primary series of 3 vaccines of which the last one was ≥ 10 years ago)
  • Provided written informed consent

Exclusion Criteria

  • Any B-cell depleting therapies in last 12 months prior to recruitment
  • Any other vaccination in last 2 months prior to recruitment
  • Any foreseeable and necessary other vaccination up to 42 days post dose 1
  • Immunoglobulin-Infusion (intravenous or subcutaneous, IVIG or SCIG) in the last 4 months prior to the drawing of study samples

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: COHORT
  • Time Perspectives: PROSPECTIVE

Cohorts and Interventions

Group / Cohort
Primary vaccination series or Booser against TBE in patients with MS

According to Swiss guidelines, patients with MS will receive the primary vaccination series (3 doses) against TBE (if they have never been vaccinated) or a TBE booster (if they have already received the primary vaccination series and their last vaccination was ≥ 10 years ago).

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Primary immunogenicity endpoint
Time Frame: 42 days post dose 1

Change in antibody concentration (GMC) from baseline to day 42 post dose 1 as measured by ELISA

42 days post dose 1

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Immunogenicity endpoint
Time Frame: 42 days post dose 1

Change in antibody titers as measured by serum neutralizing test (SNT) from baseline to day 42 (post dose 1)

42 days post dose 1
Immunogenicity endpoint
Time Frame: 7 months post dose 1 or 6 months post booster dose

Change in antibody titers as measured by ELISA from baseline to week 9 and month 7 post dose 1 if primary vaccination resp. from baseline to month 6 post booster dose.

7 months post dose 1 or 6 months post booster dose
Immunogenicity endpoint
Time Frame: 7 months post dose 1 or 6 months post booster dose

Change in antibody titers as measured by SNT from baseline to week 9 and month 7 post dose 1 if primary vaccination resp. from baseline to month 6 post booster dose.

7 months post dose 1 or 6 months post booster dose
Immunogenicity endpoint
Time Frame: at each time point (7 months)

Seropositivity as measured by ELISA . Seropositivity is defined as IgG antibody concentration >150 U/ml for ELISA.

at each time point (7 months)
Immunogenicity endpoint
Time Frame: at each time point (7 months)

Seropositivity as measured by SNT at each time point. Seropositivity is defined as antibody titer >1:10 for SNT.

at each time point (7 months)
Safety endpoint
Time Frame: 42 (+/-7d) post dose 1

The investigators will analyse indicators of disease activity through different indicators only up to day 42 (+/-7d) post dose 1

- Incidence of MS-relapses - defined clinically, according to clinical expert judgement, by the presence of MS-typical symptoms with objectifiable findings lasting more than 24 hours, without fever or infection.

42 (+/-7d) post dose 1
Safety endpoint
Time Frame: 42 (+/-7d) post dose 1

The investigators will analyse indicators of disease activity through different indicators only up to day 42 (+/-7d) post dose 1

- Activity in cerebral MRI scan (new or enlarging lesions or gadolinium uptake)

42 (+/-7d) post dose 1
Safety endpoint
Time Frame: 42 (+/-7d) post dose 1

The investigators will analyse indicators of disease activity through different indicators only up to day 42 (+/-7d) post dose 1

- Neurological assessment (EDSS)

42 (+/-7d) post dose 1
Safety endpoint
Time Frame: 42 (+/-7d) post dose 1

The investigators will analyse indicators of disease activity through different indicators only up to day 42 (+/-7d) post dose 1

- Multivariable blood biomarker based scores for MS disease activity (MSDA) and disease pathways (Octave Bioscience, USA)

42 (+/-7d) post dose 1
Safety endpoint
Time Frame: 42 (+/-7d) post dose 1

The investigators will analyse indicators of disease activity through different indicators only up to day 42 (+/-7d) post dose 1

- Vaccine reactogenicity (solicited and unsolicited local and systemic vaccine reactions)

42 (+/-7d) post dose 1

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 22, 2026

Primary Completion (Estimated)

May 31, 2027

Study Completion (Estimated)

May 31, 2027

Study Registration Dates

First Submitted

August 28, 2026

First Submitted That Met QC Criteria

November 17, 2026

First Posted (Actual)

November 19, 2026

Study Record Updates

Last Update Posted (Actual)

November 19, 2026

Last Update Submitted That Met QC Criteria

November 17, 2026

Last Verified

June 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.